Literature DB >> 7711731

Molecular dissection of a contiguous gene syndrome: localization of the genes involved in the Langer-Giedion syndrome.

H J Lüdecke1, M J Wagner, J Nardmann, B La Pillo, J E Parrish, P J Willems, E A Haan, M Frydman, G J Hamers, D E Wells.   

Abstract

The Langer-Giedion syndrome (tricho-rhino-phalangeal syndrome type II, TRPS II) is characterized by craniofacial dysmorphism and skeletal abnormalities. It combines the clinical features of TRPS I and multiple cartilaginous exostoses (EXT). We have used YAC cloning, Southern blotting, PCR analysis, and fluorescence in situ hybridization to study chromosome 8 deletions, translocations, an inversion, and an insertion in patients with TRPS I, TRPS II or EXT. Our results indicate that the TRPS gene maps more than 1,000 kb proximal to the EXT1 gene and that both genes are affected in TRPS II. We conclude that TRPS II is not due to pleiotropic effects of mutations in a single gene, but that it is a true contiguous gene syndrome.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7711731     DOI: 10.1093/hmg/4.1.31

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  27 in total

Review 1.  The link between heparan sulfate and hereditary bone disease: finding a function for the EXT family of putative tumor suppressor proteins.

Authors:  G Duncan; C McCormick; F Tufaro
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

2.  A 4 Mb cryptic deletion associated with inv(8)(q13.1q24.11) in a patient with trichorhinophalangeal syndrome type I.

Authors:  T Sasaki; H Tonoki; H Soejima; N Niikawa
Journal:  J Med Genet       Date:  1997-04       Impact factor: 6.318

3.  Deletion of 8q24 in an adult with mild dysmorphic features, developmental delay, and ketotic hypoglycemia.

Authors:  Benjamin D Solomon; Eileen Lange; Jay Shubrook; F John Service; Gail Herman; Rajaram J Karne; Phillip Gorden; Maximilian Muenke; Constantine A Stratakis
Journal:  Am J Med Genet A       Date:  2010-06       Impact factor: 2.802

4.  Delineation of a contiguous gene syndrome with multiple exostoses, enlarged parietal foramina, craniofacial dysostosis, and mental retardation, caused by deletions in the short arm of chromosome 11.

Authors:  O Bartsch; W Wuyts; W Van Hul; J T Hecht; P Meinecke; D Hogue; W Werner; B Zabel; G K Hinkel; C M Powell; L G Shaffer; P J Willems
Journal:  Am J Hum Genet       Date:  1996-04       Impact factor: 11.025

5.  Chromosome 1p36 deletions: the clinical phenotype and molecular characterization of a common newly delineated syndrome.

Authors:  S K Shapira; C McCaskill; H Northrup; A S Spikes; F F Elder; V R Sutton; J R Korenberg; F Greenberg; L G Shaffer
Journal:  Am J Hum Genet       Date:  1997-09       Impact factor: 11.025

6.  Mutation screening of the EXT1 and EXT2 genes in patients with hereditary multiple exostoses.

Authors:  C Philippe; D E Porter; M E Emerton; D E Wells; A H Simpson; A P Monaco
Journal:  Am J Hum Genet       Date:  1997-09       Impact factor: 11.025

7.  The Co-Occurrence of Tricho-Rhino-Phalangeal Syndrome and Early-Onset Levodopa-Sensitive Parkinsonism.

Authors:  Franziska Hopfner; Almuth Caliebe; Günther Deuschl; Susanne A Schneider
Journal:  Mov Disord Clin Pract       Date:  2014-09-24

8.  Mutations in the EXT1 and EXT2 genes in hereditary multiple exostoses.

Authors:  W Wuyts; W Van Hul; K De Boulle; J Hendrickx; E Bakker; F Vanhoenacker; F Mollica; H J Lüdecke; B S Sayli; U E Pazzaglia; G Mortier; B Hamel; E U Conrad; M Matsushita; W H Raskind; P J Willems
Journal:  Am J Hum Genet       Date:  1998-02       Impact factor: 11.025

Review 9.  Of hedgehogs and hereditary bone tumors: re-examination of the pathogenesis of osteochondromas.

Authors:  Kevin B Jones; Jose A Morcuende
Journal:  Iowa Orthop J       Date:  2003

Review 10.  Congenital disorders of glycosylation: review of their molecular bases, clinical presentations and specific therapies.

Authors:  T Marquardt; J Denecke
Journal:  Eur J Pediatr       Date:  2003-03-15       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.